Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 10.6% – What’s Next?

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price traded up 10.6% during mid-day trading on Thursday . The company traded as high as $20.35 and last traded at $20.16. 285,948 shares were traded during mid-day trading, a decline of 75% from the average session volume of 1,141,996 shares. The stock had previously closed at $18.23.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CAPR. Piper Sandler started coverage on Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target for the company. Maxim Group increased their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 target price on shares of Capricor Therapeutics in a report on Friday, September 20th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, October 9th. Finally, Oppenheimer reiterated an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $24.67.

Capricor Therapeutics Price Performance

The company has a market cap of $858.70 million, a price-to-earnings ratio of -21.61 and a beta of 4.00. The firm has a 50-day moving average price of $13.22 and a 200 day moving average price of $7.82.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The firm had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. On average, equities analysts anticipate that Capricor Therapeutics Inc will post -1.17 EPS for the current fiscal year.

Insider Buying and Selling

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction on Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the transaction, the insider now directly owns 7,090,351 shares in the company, valued at approximately $38,004,281.36. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 12.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CAPR. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics during the first quarter worth about $40,000. SG Americas Securities LLC acquired a new position in Capricor Therapeutics during the third quarter valued at approximately $133,000. Main Street Financial Solutions LLC lifted its stake in Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Capricor Therapeutics in the 2nd quarter valued at $147,000. Finally, Oppenheimer & Co. Inc. increased its stake in shares of Capricor Therapeutics by 25.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock valued at $1,040,000 after purchasing an additional 13,762 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.